Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Items 501–535 of 535
Network Toxicology Reveals the Mechanisms of the Plasticizer Metabolite MECPP in Metabolic Diseases
Qiu, J., Cheng, C., Jiang, B., Yang, D., & Peng, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083550 · Cited by 1
“Insulin resistance is especially relevant in this context, as it has been linked not only to systemic metabolic dysfunction but also to endothelial impairment, vascular inflammation, and hepatic lipid accumulation [29,30].”
Liu, H., Hou, Y., Yu, S., Wu, Z., Liu, J., Shi, W., & Yan, G. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1822295 · Cited by 1
Pan, H., Zhang, Q., Wang, Y., Chen, A., Chen, X., Ren, L., & Miao, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1776998
Hassen, H., Tarko, T., & Franczyk‐Żarów, M. (2026) · Applied Sciences · doi:10.3390/app16115254
Chen, L. X., Fan, G., Yuan, Q., Gang, G. U. O., & Zhou, J. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s586439
Guo, Y., Zhou, X., Chen, L., & Zheng, J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s602358
Ma, X. C., Chu, H., Li, Q., Yang, Y., & Wang, Z. (2026) · Mediators of Inflammation · doi:10.1155/mi/7921309
Ren, L., Liu, D., Zhou, B., Liu, J., & Yu, C. (2026) · Journal of Health Population and Nutrition · doi:10.1186/s41043-026-01369-9
“IR can promote the occurrence of cardiovascular and cerebrovascular events through multiple pathways, including the induction of chronic inflammation, exacerbation of oxidative stress, impairment of endothelial function, and facilitation of atherosclerosis development [30–32].”
Wang, Y., Lei, Q., Wang, J., Lin, Y., & Xu, L. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1838009
“It contributes to atherosclerotic progression, endothelial dysfunction, inflammatory activation, and thrombosis (19) and has also been linked to an increased risk of ischemic stroke (20).”
Shen, J., Peng, S., Du, J., Xu, Z., Wang, D., Lv, M., Duan, Y., & Wei, W. (2026) · World Neurosurgery X · doi:10.1016/j.wnsx.2026.100613
Jiang, Y., Liu, M., Chen, H., Zhang, F., Liu, S., Li, X., Guo, T., Xiong, Z., Shen, Q., & Xiong, X. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02986-3
“At the cellular level, it promotes endothelial and smooth muscle dysfunction [36], oxidative stress [37], lipid metabolic abnormalities [38], and activation of inflammatory pathways [39].”
Xie, Z., Liu, G., Ge, R., Liao, Q., & Li, Z. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03533-8
Lei, J., Zhuang, Y., Zhao, X., Chen, Y., Tang, S., Han, Y., Zhao, Y., Liu, Y., & Fan, Z. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm46005
Yao, X., Liang, L., Chen, J., Yang, M., Liang, Y., & Fang, X. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03134-5 · Cited by 1
“Several mechanistic hypotheses have been suggested, with chief among them being metabolic dysregulation, endothelial dysfunction and oxidative stress, alongside enhanced inflammatory responses and abnormal activation of the renin-angiotensin-aldosterone system (RAAS) [ 9, 10 ].”
Dai, L., Sun, Y., Yin, J., Jiang, Y., Li, H., Wang, Y., & Meng, X. (2026) · BMC Neurology · doi:10.1186/s12883-026-05141-8
Multifaceted roles of Isthmin-1 in health and disease: mechanism and therapeutic intervention
Wei, Y. M., Wu, W., Hou, Y., Zhang, Y., Zhao, K., & Ding, W. (2026) · Clinical Science · doi:10.1042/cs20260727
Tang, P., Cui, M., Li, R., Jiang, F., & Cui, X. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06330-6
“Insulin resistance is a central pathophysiological driver of atherogenesis, contributing to dyslipidemia, endothelial dysfunction, oxidative stress, and chronic low-grade inflammation [8, 9].”
Li, C., Xie, Y., Pan, W., Qin, D., & Mi, H. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2684346
Ramezankhani, A., Barzin, M., Azizi, F., & Hadaegh, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.034
Luo, L., Wang, L., Yu, X., Yang, Q., Ming, X., Xiong, H., Li, D., & Yan, X. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03318-6
Avidan, Y., Halon, D. A., Yahav, A., Popović, D., Arena, R. A., & Zafrir, B. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103420 · Cited by 1
WHY SARCOPENIC OBESITY IS THE STRATEGIC INTERSECTION? – A NARRATIVE REVIEW
Słowik, M., Świercz, J., Arciszewski, K., Hariasz, N., Orda, K., Walczak, D., Szumiło, J., Kasperska, K., Markiv, M., & Stenzel, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6343
Cai, H., Fu, Y., Zhu, F., Qiu, J., Ye, H., & Xie, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71280
Zhang, S., Li, X., Li, J., Xie, S., Wang, Z., Zheng, Z., Huang, J., & Zhou, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1855099
“Insulin resistance (IR) has been proposed as a key biological link between COPD and PD (6, 7).”
Naman, T., Cheng, H., Yu, X., & Guo, Z. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03693-w
“…by impaired glucose absorption and oxidization [28, 29]; high IR leads to endothelial impairment [28], ectopic angiotensinogen generation [30], or even renin-angiotensin-aldosterone system (RAAS) activation [31] and systemic low-grade inflammation, which exacerbates HF progression [32, 33].”
Luo, H., Wang, X., Zhang, C., He, J., Sun, M., Yang, Y., Wang, M., Hu, R., Xiao, S., Chen, Z., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1917797
Tang, Y., Xu, Y., Yue, Z., Wang, W., Song, W., Wang, H., Liu, L., Wu, J., & Sun, Z. (2026) · iScience · doi:10.1016/j.isci.2026.117400 · Cited by 1
Deng, Z., Zheng, J., Ye, Y., Chen, F., Liu, H., Wang, X., Liu, Q., Lyu, C., Liu, C., Liu, L., et al. (2026) · Lupus Science & Medicine · doi:10.1136/lupus-2026-002141
Huang, C., Tong, Y., Luo, Y., & Xie, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1952432
Cui, Z., Lan, T., Lu, M., Zhang, N., Yang, D., Xuhrat, X., Kang, M., Kuang, J., Turghun, D., Wen, T., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1967131
Wang, X., Ma, S., Hai, X., Ma, A., Wu, P., Liang, X., Hao, Y., 杨利波, & Yan, N. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/4209201
Kim, M. J., Kim, Y. J., Kang, J.-H., & Bae, Y. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1976562
Cai, H., Fu, Y., Zhu, F., Qiu, J., Ye, H., & Xie, E. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06822-5
“Insulin resistance promotes impaired glucose metabolism, endothelial dysfunction, vascular inflammation, and atherosclerotic progression [10, 11], whereas atherogenic dyslipidemia, typically characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol, contributes to…”
Zhao, L. Y., Wu, D., Zhang, Z., Li, T., Gao, T., Wu, S., Wang, B., Liu, M., Yang, P., Tan, J., et al. (2026) · Open Heart · doi:10.1136/openhrt-2026-004434
Xiong, L., Huang, Y., He, S., Zhu, Y., Ren, J., Qiao, S., Tang, C., Peng, H., & Gu, X. (2026) · Heart and Mind · doi:10.4103/hm.hm-d-26-00044
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.